BIORA THERAPEUTICS, INC. short interest in 2022
In 2022, BIORA THERAPEUTICS, INC.'s disclosed short interest ran from 7.06% of shares outstanding on 14 Jan 2022 to 5.99% on 30 Dec 2022, a change of -1.07 percentage points. The year's high was 11.42% on 29 Apr 2022 and its low 5.99% on 30 Dec 2022, averaging 8.25% across 20 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 18.14 days on 15 Sep 2022. Full history: BIORA THERAPEUTICS, INC..
Cite this page
By year: 2020 · 2021 · 2022 · 2023 · 2024
2022 in figures
- Start of year
- 7.06% (14 Jan 2022)
- End of year
- 5.99% (30 Dec 2022)
- Change
- -1.07 pp
- High
- 11.42% (29 Apr 2022)
- Low
- 5.99% (30 Dec 2022)
- Average
- 8.25%
- Highest days to cover
- 18.14 (15 Sep 2022)
- SEC filings marked
- 8
Every report in 2022
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 14 Jan 2022 | 7.06% | 1.28 | |
| 31 Jan 2022 | 6.91% | 1.02 | |
| 15 Feb 2022 | 8.09% | 1.35 | |
| 28 Feb 2022 | 9.98% | 1.96 | |
| 15 Mar 2022 | 9.12% | 3.08 | |
| 31 Mar 2022 | 10.66% | 1.58 | 10-K filed, results (8-K) |
| 14 Apr 2022 | 11.21% | 3.43 | |
| 29 Apr 2022 | 11.42% | 6.07 | |
| 15 Jul 2022 | 9.72% | 10.60 | 10-Q filed, results (8-K) |
| 29 Jul 2022 | 8.73% | 12.25 | |
| 15 Aug 2022 | 8.51% | 3.52 | 10-Q filed, results (8-K) |
| 31 Aug 2022 | 7.90% | 11.44 | |
| 15 Sep 2022 | 7.89% | 18.14 | |
| 30 Sep 2022 | 7.54% | 11.54 | |
| 14 Oct 2022 | 7.62% | 12.77 | |
| 31 Oct 2022 | 7.43% | 14.04 | |
| 15 Nov 2022 | 6.80% | 6.54 | 10-Q filed, results (8-K) |
| 30 Nov 2022 | 6.28% | 8.41 | |
| 15 Dec 2022 | 6.16% | 7.30 | |
| 30 Dec 2022 | 5.99% | 5.71 |
See also: BIORA THERAPEUTICS, INC.'s full history · most shorted US stocks of 2022 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.